ReviewCJC open2024
Malignant Pericardial Effusion: A Systematic Review.
Review in CJC open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Clinical Characteristics and Outcomes of Patients Undergoing Pericardiocentesis for Pericardial Effusion: A Single-Center Experience with Exploratory Inflammatory Biomarker Analysis.Journal of clinical medicine · 2026Article
- AI-Derived Pericardial Effusion Volume and Long-Term Mortality After Transcatheter Aortic Valve Implantation.Journal of clinical medicine · 2026Article
- Prognostic Factors and Survival in Pericardial Mesothelioma: A Systematic Review and Quantitative Analysis.Cancers · 2026Review
- Long-term mortality and acute complications after percutaneous pericardiocentesis in cancer and noncancer patients presenting with severe pericardial effusion.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Subacute normotensive cardiac tamponade as the initial presentation of metastatic lung adenocarcinoma: a case report.Journal of medical case reports · 2026Article
- Urothelial Carcinoma With Pericardial Involvement: Report of Two Rare Cases and Literature Review.Case reports in oncological medicine · 2026Article
- When the Heart Is the Target: Case of Primary Pericardial Diffuse Large B-Cell Lymphoma Presenting With Tamponade.Case reports in oncological medicine · 2026Article
- Malignant Pericardial Effusion: Heart-Breaking Tumors.Methodist DeBakey cardiovascular journal · 2026Review
- Risk of Cancer After a Hospital Contact for Dyspnea: A Nationwide Danish Cohort Study.Clinical epidemiology · 2026Article
- Surgical Management Strategies for Pericardial Effusion-A Systematic Review.Journal of clinical medicine · 2025Review
- The Value of Thin Layer Cytology in Cancer Patients' Pericardial Effusions.Current oncology (Toronto, Ont.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Malignant pericardial effusion (Eff) is often asymptomatic and has an unknown prevalence, due to its occult presentation. The condition often is identified postmortem on autopsy, and it is associated with a poor prognosis. Given the late presentation of malignant pericardial Effs, a minimal volume of literature has examined the epidemiology, clinical characteristics, and outcomes of these complex patients. We conducted a systematic review to advance present understanding of this condition. Methods: A search of 4 databases resulted in 41 case reports meeting criteria. Inclusion criteria were being a patient aged > 18 years who presented with pericardial Eff in the setting of malignancy. Intervention was medical and/or surgical therapy, and the outcome was mortality. Results: For the 41 patients included, the median age was 54 years, and the majority were male patients (58%). Dyspnea was the leading symptom (90%), and cardiac tamponade was present in 78% of cases. Common cancers included lung, gastrointestinal, and renal neoplasms (59%). Pericardiocentesis occurred in 98% of cases, with a median fluid extraction volume of 1000 mL. Death occurred in 44%, primarily due to disease progression and/or metastasis. Conclusions: This study presents the largest systematic review on malignancy-induced pericardial Effs to date. Notably, solid tumours, and specifically lung adenocarcinomas, are common culprits. Malignant pericardial Effs are often severe, with a majority of patients presenting with cardiac tamponade. Overall, treatment options are limited, and the associated mortality rate is high.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.